| Title |
Preventing the common cold with a garlic supplement: A double-blind, placebo-controlled survey
|
|---|---|
| Published in |
Advances in Therapy, July 2001
|
| DOI | 10.1007/bf02850113 |
| Pubmed ID | |
| Authors |
Peter Josling |
| Abstract |
One hundred forty-six volunteers were randomized to receive a placebo or an allicin-containing garlic supplement, one capsule daily, over a 12-week period between November and February. They used a five-point scale to assess their health and recorded any common cold infections and symptoms in a daily diary. The active-treatment group had significantly fewer colds than the placebo group (24 vs 65, P < .001). The placebo group, in contrast, recorded significantly more days challenged virally (366 vs 111, P < .05) and a significantly longer duration of symptoms (5.01 vs 1.52 days, P < .001). Consequently, volunteers in the active group were less likely to get a cold and recovered faster if infected. Volunteers taking placebo were much more likely to get more than one cold over the treatment period. An allicin-containing supplement can prevent attack by the common cold virus. |
X Demographics
The data shown below were collected from the profiles of 213 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 37 | 17% |
| United Kingdom | 12 | 6% |
| India | 7 | 3% |
| Spain | 6 | 3% |
| Canada | 6 | 3% |
| Saudi Arabia | 5 | 2% |
| Kenya | 3 | 1% |
| Argentina | 2 | <1% |
| Australia | 2 | <1% |
| Other | 26 | 12% |
| Unknown | 107 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 183 | 86% |
| Practitioners (doctors, other healthcare professionals) | 24 | 11% |
| Scientists | 5 | 2% |
| Science communicators (journalists, bloggers, editors) | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Greece | 1 | 1% |
| Unknown | 87 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 24 | 27% |
| Student > Master | 14 | 16% |
| Other | 8 | 9% |
| Student > Ph. D. Student | 7 | 8% |
| Researcher | 6 | 7% |
| Other | 12 | 14% |
| Unknown | 17 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 25% |
| Agricultural and Biological Sciences | 13 | 15% |
| Nursing and Health Professions | 7 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 8% |
| Biochemistry, Genetics and Molecular Biology | 5 | 6% |
| Other | 13 | 15% |
| Unknown | 21 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 829. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 April 2024.
All research outputs
#22,587
of 25,743,152 outputs
Outputs from Advances in Therapy
#1
of 2,680 outputs
Outputs of similar age
#5
of 41,209 outputs
Outputs of similar age from Advances in Therapy
#1
of 4 outputs
Altmetric has tracked 25,743,152 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,680 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 41,209 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them